Pingili Chandra Shekar, Okon Emmanuel E
Department of Infectious Diseases, Prevea Health, Sacred Heart Hospital, Eau Claire, WI, USA.
Prevea Health, Eau Claire, WI, USA.
Am J Case Rep. 2017 Sep 25;18:1024-1027. doi: 10.12659/ajcr.905214.
BACKGROUND Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and sepsis are commonly treated with intravenous vancomycin. However, vancomycin treatment is associated adverse reactions, including skin rashes and nephrotoxicity. We present a case of acute renal failure due to acute tubulointerstitial nephritis associated with a diffuse leukocytoclastic vasculitic skin eruption following intravenous vancomycin treatment. CASE REPORT A 79-year-old Caucasian male patient was treated with intravenous vancomycin for MRSA bacteremia. Prior to treatment, his creatinine was normal at 0.6 mg/dl. He presented one week later with shortness of breath, lower limb edema, and acute renal failure. He had a diffuse maculopapular rash involving the trunk and both upper and lower extremities. A renal biopsy and left arm skin biopsy were examined histologically. The skin biopsy showed leukocytoclastic vasculitis. Renal biopsy showed some sclerosed glomeruli, some with mesangial proliferation, and tubulointerstitial inflammation with eosinophils and plasma cells and mild interstitial fibrosis. Although there was some renal arteriolosclerosis, no vasculitic changes were seen, and no vascular thrombosis was present. A diagnosis of leukocytoclastic vasculitis and acute tubulointerstitial nephritis secondary to intravenous vancomycin therapy was made. CONCLUSIONS Although skin reactions associated with drug therapy are common, vancomycin-associated dermal vasculitis is rare. Tubulointerstitial nephritis is also a rare association with vancomycin treatment. This case report has highlighted that patients being treated with intravenous vancomycin should be carefully observed for acute skin rashes and deterioration in renal function, which can be managed by ceasing treatment with vancomycin, steroid challenge, and preventing future exposure to similar antimicrobial agents.
耐甲氧西林金黄色葡萄球菌(MRSA)菌血症和败血症通常用静脉注射万古霉素治疗。然而,万古霉素治疗会引发不良反应,包括皮疹和肾毒性。我们报告一例因静脉注射万古霉素治疗后出现弥漫性白细胞破碎性血管炎皮疹伴发急性肾小管间质性肾炎导致的急性肾衰竭病例。
一名79岁的白人男性患者因MRSA菌血症接受静脉注射万古霉素治疗。治疗前,他的肌酐水平正常,为0.6mg/dl。一周后,他出现呼吸急促、下肢水肿和急性肾衰竭。他的躯干及上下肢出现弥漫性斑丘疹。对肾脏活检组织和左臂皮肤活检组织进行了组织学检查。皮肤活检显示白细胞破碎性血管炎。肾脏活检显示一些肾小球硬化,部分伴有系膜增生,肾小管间质有嗜酸性粒细胞和浆细胞炎症以及轻度间质纤维化。虽然存在一些肾小动脉硬化,但未见血管炎改变,也无血管血栓形成。诊断为静脉注射万古霉素治疗继发的白细胞破碎性血管炎和急性肾小管间质性肾炎。
虽然药物治疗相关的皮肤反应很常见,但万古霉素相关的皮肤血管炎很少见。肾小管间质性肾炎与万古霉素治疗的关联也很罕见。本病例报告强调,接受静脉注射万古霉素治疗的患者应仔细观察是否出现急性皮疹和肾功能恶化情况,可通过停用万古霉素、使用类固醇药物及避免未来接触类似抗菌药物来处理。